Xing Zhou

机构：China Pharmaceutical University, Kunming Medical University, First Affiliated Hospital of Zhengzhou University · ORCID：0000-0002-9251-7714

发表论文 76 篇 · 总被引 14413 次 · h-index 20

代表论文

• THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer (2024 · Molecular Cancer · 被引 88)
• THBS2-producing matrix CAFs promote colorectal cancer progression and link to poor prognosis via the CD47-MAPK axis (2025 · Cell Reports · 被引 25)
• FOS-driven inflammatory CAFs promote colorectal cancer liver metastasis via the SFRP1-FGFR2-HIF1 axis (2025 · Theranostics · 被引 21)
• Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives (2025 · Molecular Cancer · 被引 16)
• Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance (2025 · Journal of Nanobiotechnology · 被引 13)
• Cancer-associated fibroblasts enhance colorectal cancer lymphatic metastasis via CLEC11A/LGR5-mediated WNT pathway activation (2025 · Journal of Clinical Investigation · 被引 8)